ProgenaMatrix™ is currently being evaluated in a select high-volume wound clinic in New York City for the venous leg ulcer (VLU) patient population.
Venous leg ulcers are a common problem in patients with venous insufficiency. Approximately 7 million people in the U.S. have venous insufficiency and it’s estimated that 1 million people will develop a VLU. These VLU wounds often recur, and the wounds can persist for months or even years, potentially leading to complications such as cellulitis, osteomyelitis or malignant change.1
1. Agale SV. Chronic leg ulcers: epidemiology, aetiopathogenesis and Management. Hindawi Publishing Corporation 2013;13.
ProgenaMatrix™ is a medical device cleared by the US FDA for the treatment of dry and exuding partial and full thickness wounds.